- Home
- MRSN vs NVA Comparison
MRSN vs NVA Comparison
Compare MRSN & NVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- NVA
- Stock Information
- Founded
- MRSN 2001
- NVA 1987
- Country
- MRSN United States
- NVA Australia
- Employees
- MRSN N/A
- NVA N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- NVA
- Sector
- MRSN Health Care
- NVA
- Exchange
- MRSN Nasdaq
- NVA NYSE
- Market Cap
- MRSN 71.9M
- NVA 53.1M
- IPO Year
- MRSN 2017
- NVA N/A
- Fundamental
- Price
- MRSN $0.48
- NVA $11.27
- Analyst Decision
- MRSN Buy
- NVA
- Analyst Count
- MRSN 4
- NVA 0
- Target Price
- MRSN $4.33
- NVA N/A
- AVG Volume (30 Days)
- MRSN 3.8M
- NVA 22.9K
- Earning Date
- MRSN 03-03-2025
- NVA 01-01-0001
- Dividend Yield
- MRSN N/A
- NVA N/A
- EPS Growth
- MRSN N/A
- NVA N/A
- EPS
- MRSN N/A
- NVA N/A
- Revenue
- MRSN $40,497,000.00
- NVA N/A
- Revenue This Year
- MRSN N/A
- NVA N/A
- Revenue Next Year
- MRSN $67.68
- NVA N/A
- P/E Ratio
- MRSN N/A
- NVA N/A
- Revenue Growth
- MRSN 9.88
- NVA N/A
- 52 Week Low
- MRSN $0.45
- NVA $4.35
- 52 Week High
- MRSN $5.96
- NVA $19.00
- Technical
- Relative Strength Index (RSI)
- MRSN 35.88
- NVA N/A
- Support Level
- MRSN $0.49
- NVA N/A
- Resistance Level
- MRSN $0.56
- NVA N/A
- Average True Range (ATR)
- MRSN 0.05
- NVA 0.00
- MACD
- MRSN 0.02
- NVA 0.00
- Stochastic Oscillator
- MRSN 28.11
- NVA 0.00
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About NVA NOVA MINERALS LTD SPON ADS EACH REP 60 ORD
Nova Minerals Ltd is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project. It includes projects such as Estelle Gold and Critical Minerals Project, RPM, Korbel, Train and Stoney. It operates in one segment which is exploration of minerals and two geographical areas, being Australia and United States, where Australia derives maximum revenue.